Evidence mapPaperPMID 41940800Full record

ArticleJournal of medicinal chemistry2026

GV-001, An Oral Available Histone Deacetylase 6 Inhibitor for the Treatment of Autosomal Dominant Polycystic Kidney Disease.

Sian-Siou Wu, Pei-Yun Hung, Tsung-Yu Yeh, Po-Jui Lin, Ji-Wang Chern, Chao-Wu Yu

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sian-Siou WuSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei 100, Taiwan.
Pei-Yun HungGilva Therapeutics Co., Ltd., Taipei 100, Taiwan.
Tsung-Yu YehSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei 100, Taiwan.ORCID 0000-0001-7812-5290
Po-Jui LinSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei 100, Taiwan.
Ji-Wang ChernGilva Therapeutics Co., Ltd., Taipei 100, Taiwan.ORCID 0000-0002-4310-8834
Chao-Wu YuSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei 100, Taiwan.ORCID 0000-0002-5176-4225

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a rare genetic disorder characterized by progressive cyst formation. Emerging evidence suggests that histone deacetylase 6 (HDAC6) plays a pivotal role in the regulation of disease progression. In this study, a series of quinazoli-4-one derivatives were designed and synthesized, among which compound

Indexed as

Histone Deacetylase 6Histone Deacetylase InhibitorsPolycystic Kidney, Autosomal DominantAdministration, OralAnimalsHumansKidneyMaleMiceRatsRats, Sprague-DawleyStructure-Activity RelationshipHDAC6 protein, humanHistone Deacetylase 6Histone Deacetylase Inhibitors

Identifiers

PMID41940800
PMCPMC13181768

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.